View Older Stories View More Recent Stories
-
Citizens JMP: Standard of Care Modifying Regimens at ASCO 2025
-
Danaher (DHR) Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine
-
FDA Mandates Trials For Covid Boosters For Healthy Kids, Adults - NEJM
-
AstraZeneca (AZN) reveals positive results from BATURA Phase 3b trial
-
Airsupra shows significant improvement in asthma treatment, AstraZeneca (AZN) reveals
-
AstraZeneca (AZN) Reports IMFINZI regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTO
-
Bernstein explains why share price rally in this pharma stock should continue
-
AstraZeneca (AZN) reports BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma
-
AstraZeneca (AZN) Tops Q1 EPS by 139c
-
SOPHiA GENETICS (SOPH) Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR
-
Tempus AI (TEM) Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology
-
AstraZeneca is due to report next week. Here's what analysts expect
-
BNP Paribas Exane Starts AstraZeneca (AZN:LN) (AZN) at Outperform
-
Pharma stocks slide after Trump signals tariffs on sector
-
AstraZeneca (AZN) Announces ENHERTU Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer
-
AstraZeneca (AZN) reports that AZD0780 demonstrated significant LDL cholesterol reduction in PURSUIT Phase IIb trial
-
AstraZeneca (AZN): IMFINZI approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
-
Goldman Sachs on AstraZeneca (AZN): 'we are positive on the long-term outlook and like the company's strategy'
-
AstraZeneca (AZN:LN) (AZN) PT Raised to GBP151.30 at Goldman Sachs
-
Truist Weighs In on Obesity: 'Catalyst-Rich 2025 Ahead in a Growing Competitive Landscape'
-
AstraZeneca (AZN) and Harbour BioMed Enter Global Strategic Collaboration to Discover and Develop Next-Generation Therapeutic Antibodies
-
AstraZeneca (AZN) to invest $2.5B in new global strategic R&D centre, biotech agreements and manufacturing in Beijing
-
TD Cowen Highlights AstraZeneca's (AZN) 'Attractive Valuation'; Stock Named Europe Best Ideas
-
AstraZeneca (AZN) to acquire EsoBiotec
-
AstraZeneca (AZN): IMFINZI (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement
-
These 5 stocks are latest additions to Goldman's 'European Conviction List - Directors’ Cut' list
-
AstraZeneca (AZN) reports ENHERTU Recommended for Approval in the EU by CHMP
-
AstraZeneca (AZN) reports Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer w
-
FINAL REMINDER AZN DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts AstraZeneca PLC Investors to Participate in the Class Action Lawsuit
-
AZN DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages AstraZeneca PLC Investors to Secure Counsel Before Important February 21 Deadline in Securities Class Action First Filed by the Firm - AZN
-
FINAL AZN DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds AstraZeneca PLC Investors to Join the Class Action Lawsuit
-
AZN FINAL DEADLINE ALERT: AstraZeneca (AZN) Investors with Losses Encouraged to Contact Hagens Berman Before Feb. 21, 2025 Deadline in Securities Class Action
-
FibroGen (FGEN) Sells FibroGen China to AstraZeneca (AZN) for $160M
-
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca
-
AstraZeneca (AZN) Hit With US Class Action Lawsuit Over China Regulatory Probes - FT
-
AZN DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important February 21 Deadline in Securities Class Action First Filed by the Firm - AZN
-
AZN DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important February 21 Deadline in Securities Class Action First Filed by the Firm - AZN
-
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca
-
AZN DEADLINE ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important February 21 Deadline in Securities Class Action First Filed by th
-
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca
-
AZN DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important February 21 Deadline in Securities Class Action First Filed by the Firm -
-
This pharma stock has rich catalyst path, attractive valuation: BofA
-
AZN DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important February 21 Deadline in Securities Class Action First Filed by the Firm - AZN
-
AstraZeneca (AZN) Faces Securities Class Action After Reports of PRC Probe into Fraud and Corruption - Hagens Berman
-
UBS Upgrades AstraZeneca (AZN:LN) (AZN) to Buy
-
AZN DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important February 21 Deadline in Securities Class Action First Filed by the Firm - A
-
BofA Securities Reiterates Buy Rating on AstraZeneca (AZN:LN) (AZN)
-
Morgan Stanley Starts AstraZeneca (AZN:LN) (AZN) at Overweight
-
Faruqi & Faruqi Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 - AZN
-
ROSEN, A TOP RANKED LAW FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important February 21 Deadline in Securities Class Action First Filed by the Firm - AZN
